Dilip Viswanath, MD
Cardiovascular Disease · Haddon Heights, NJNPI 1528019262
Payments from drug & device makers
Across 958 payments — averaging $1858.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.3M
- Merck$92K
- Esperion Therapeutics, Inc.$87K
- Johnson & Johnson$86K
- AstraZeneca$83K
- Boston Scientific$58K
- plus $46K from 31 others
What the payments were for
- Consulting fees$6,6934%
- Speaking & faculty fees$139,17983%
- Travel & lodging$3,6822%
- Food & beverage$17,30110%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 86 | $1,326,951 |
| Merck | 54 | $92,016 |
| Esperion Therapeutics, Inc. | 120 | $87,489 |
| Johnson & Johnson | 177 | $85,912 |
| AstraZeneca | 52 | $82,890 |
| Boston Scientific | 34 | $58,388 |
| Boehringer Ingelheim | 52 | $13,075 |
| Astrazeneca UK Limited | 4 | $9,525 |
| E.r. Squibb & Sons, L.L.C. | 52 | $6,508 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $5,601 |
| Impulse Dynamics (USA) Inc. | 29 | $5,424 |
| Abbott | 20 | $1,010 |
| Pfizer | 83 | $969 |
| Biotronik Inc. | 7 | $744 |
| Amgen | 48 | $728 |
| Medtronic(2 entities) | 3 | $494 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $390 |
| Bayer | 14 | $365 |
| Amarin Pharma, Inc. | 25 | $339 |
| Regeneron Healthcare Solutions, Inc. | 11 | $276 |
| Sanofi-aventis U.S. LLC | 18 | $221 |
| W. L. Gore & Associates, Inc. | 9 | $160 |
| Scpharmaceuticals Inc. | 6 | $105 |
| Biosense Webster, Inc. | 1 | $53 |
| Lundbeck LLC | 4 | $53 |
| Cvrx, Inc. | 1 | $52 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $45 |
| Heartflow, Inc. | 2 | $37 |
| Inspire Medical Systems, Inc. | 2 | $32 |
| Bridgebio Pharma, Inc. | 2 | $31 |
| Novo Nordisk | 2 | $31 |
| Regeneron | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Preventice Services, LLC | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,779,996 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $348,350 |
| XareltoRivaroxaban | 219 | $290,902 |
| FarxigaDapagliflozin Propanediol | 120 | $149,930 |
| EntrestoSacubitril/Valsartan | 58 | $84,693 |
| Repatha SureclickEvolocumab | 65 | $70,261 |
| JardianceEmpagliflozin | 41 | $46,684 |
| Praluent PenAlirocumab | 25 | $31,782 |
| MultaqDronedarone Hcl | 14 | $30,641 |
| OzempicSemaglutide | 19 | $21,493 |
| BrilintaTicagrelor | 13 | $16,130 |
| Icosapent Ethyl | 21 | $13,394 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $13,339 |
| Repatha PushtronexEvolocumab | 11 | $12,753 |
| Ezetimibe | 426 | $12,639 |
| Ranolazine ErRanolazine | 81 | $9,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $969 | $348,350283 claims |
| Johnson & JohnsonXarelto | $85,912 | $290,902219 claims |
| AstraZenecaFarxiga, Brilinta | $82,890 | $166,060133 claims |
| NovartisEntresto | $1,326,951 | $84,69358 claims |
| Boehringer IngelheimJardiance | $13,075 | $46,68441 claims |
| Sanofi-aventis U.S. LLCMultaq | $221 | $30,64114 claims |
| Novo NordiskOzempic | $31 | $21,49319 claims |
| Esperion Therapeutics, Inc.Nexlizet | $87,489 | $13,33912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Haddon Heights
- Mark GelerntHaddon Heights$2M
- Sanford GipsHaddon Heights$668K
- Andreas PavlidesHaddon Heights$598K
- Vijayendra VermaHaddon Heights$359K
- Harvey SnyderHaddon Heights$93K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Robert FishbergSpringfield$1.9M
- Marc CohenNewark$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.